A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric Participants
Trial details
- Registry ID
- NCT07727538
- Drugs studied
- Olezarsen
TrialRedline tracks 35 clinical trials sponsored by Ionis Pharmaceuticals, Inc.: 20 Phase 3, 12 Phase 2, 3 Phase 1 / 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet SyndromeNCT07531745 | ION337 | Recruiting | 2030-12Estimated |
| ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)NCT06430385 | ION440 | Recruiting | 2027-09Estimated |
| HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman SyndromeNCT05127226 | ION582 | Active not recruiting | 2032-03Estimated |
Names as written in the registry records.
NCT06914609 · Ionis Pharmaceuticals, Inc.
Before: Estimated. After: Actual.
Before: 158 participants (planned). After: 156 participants (actual).
Before: Recruiting. After: Active not recruiting.
Before: Estimated. After: Actual.
Before: Apr 2026. After: 25 Mar 2026.
Before: Active not recruiting. After: Completed.
Before: Estimated. After: Actual.
Before: Jun 2026. After: 17 Jun 2026.
NCT05143957 · Ionis Pharmaceuticals, Inc.
Before: Active not recruiting. After: Completed.
Before: 17 Jan 2023. After: 22 Mar 2023.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Percent Change From Baseline at Month 6 (average of Weeks 25 and 27) in Fasting Triglycerides (TG). After: Measure: Percent Change From Baseline in Fasting TG at Month 6.
Before: 22 Mar 2023. After: 17 Jan 2023.
NCT07298447 · Ionis Pharmaceuticals, Inc.
Before: Not yet recruiting. After: Recruiting.
NCT04307381 · Ionis Pharmaceuticals, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Percentage of Participants with at Least One Treatment-emergent Adverse Event (TEAE), Graded by Severity. After: Measure: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Measure: Percentage of Participants With Clinically Meaningful Changes in Clinical Laboratory Assessments Measure: Percentage of Participants With Clinically Meaningful Changes in Vital Signs Measure: Percentage of Participants With Clinically Meaningful Changes in Electrocardiograms (ECGs) Parameters Measure: Percentage of Participants Who Received At Least One Concomitant Medication.
NCT06914609 · Ionis Pharmaceuticals, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Change in Performance on the Expressive Communication Subdomain Raw Score of the Bayley Scales for Infant and Toddler Development-4 (Bayley-4) in Cohort 1. After: Measure: Change in Performance on the Expressive Communication Subdomain Raw Score of the Bayley Scales for Infant and Toddler Development-4 (Bayley-4) Without Caregiver Input in Cohort 1.
Before: 210 participants (planned). After: 158 participants (planned).
NCT05681351 · Ionis Pharmaceuticals, Inc.
Before: Estimated. After: Actual.
Before: 800 participants (planned). After: 885 participants (actual).
Before: Recruiting. After: Active not recruiting.
NCT04849741 · Ionis Pharmaceuticals, Inc.
Before: Estimated. After: Actual.
Before: Sep 2025. After: 22 Aug 2025.